Ayurveda in Diabetes (Prameha)

Clinical studies examine Ayurvedic interventions — classical formulations (nisha-amalaki among the most tested), single herbs (fenugreek, gymnema), and diet-yoga regimens — in type 2 diabetes (prameha/madhumeha).

Summary

Trials range from small pilot studies of classical formulations to multi-center studies of standardized herbal products; the framework is integrative (Ayurveda alongside standard care rather than replacing it).

Key findings

Modest glycemic improvements (HbA1c reductions of ~0.3–0.5% in several trials of standardized herbal interventions) are reported; safety is generally favorable in monitored trials, but publication bias and small samples are pervasive. NCCIH’s assessment: insufficient evidence to recommend Ayurvedic practice as a type-2 diabetes treatment, with some individual-herb signals (fenugreek’s fiber-mediated effects among the better documented).

Methodology

Trial quality varies widely; few blinded designs (formulation taste defeats blinding); outcome standardization is improving.

Criticism/Limitations

Heavy-metal contamination in some marketed rasa preparations is a documented safety concern; the encyclopedia distinguishes studied standardized products from unregulated market formulations.

Verification notes

• The NCCIH assessment and the trial literature’s general shape are accurately summarized.
• Audited against the clinical literature (September 2026).